$NPHC Analyst Coverage- Undervalued: http://global
Post# of 98055
(Total Views: 91)
Posted On: 02/24/2017 7:47:19 AM
$NPHC Analyst Coverage- Undervalued: http://globalsmallcaps.com/2017/02/14/nutra-pharma-corp/
We begin coverage of Nutra Pharma, Corp. with a Buy recommendation and a price target of $0.10 per share.Nutra Pharma is in the process of introducing cobra toxin-based therapies for human and pet pain management markets and additionally has therapeutic drug development opportunities relative to HIV and MS.OTC sales are being driven by retail expansion and DRTV programs.The worldwide pain management market is of significant size and is undergoing dramatic change as physicians significantly curtail narcotic prescriptions. This is creating new opportunities for innovative pain treatment therapies and products. There is much focus on this sector.The Company was recently featured in NBC news. The interview is here: www.tinyurl.com/nyloxinNBCWhile we do not believe it to be the near term market opportunity for the Company, it also has a strong pipeline of possible therapies for autoimmune diseases and HIV. Orphan drug status as been granted for RPI-78M.In our opinion, this is an innovative company with a therapy that is exciting and could capture the imagination of risk-averse investors, yielding a significantly higher, stock price.
We begin coverage of Nutra Pharma, Corp. with a Buy recommendation and a price target of $0.10 per share.Nutra Pharma is in the process of introducing cobra toxin-based therapies for human and pet pain management markets and additionally has therapeutic drug development opportunities relative to HIV and MS.OTC sales are being driven by retail expansion and DRTV programs.The worldwide pain management market is of significant size and is undergoing dramatic change as physicians significantly curtail narcotic prescriptions. This is creating new opportunities for innovative pain treatment therapies and products. There is much focus on this sector.The Company was recently featured in NBC news. The interview is here: www.tinyurl.com/nyloxinNBCWhile we do not believe it to be the near term market opportunity for the Company, it also has a strong pipeline of possible therapies for autoimmune diseases and HIV. Orphan drug status as been granted for RPI-78M.In our opinion, this is an innovative company with a therapy that is exciting and could capture the imagination of risk-averse investors, yielding a significantly higher, stock price.
(0)
(0)Scroll down for more posts ▼